# Soligenix Inc. (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer

* The global rare disease treatment market was estimated at $195.2 billion in 2024 and is anticipated to expand at a CAGR of 11.6% by 2030.
* SNGX’s HyBryte(TM) has demonstrated positive results in a study testing its use for patients with early-stage CTCL.
* HyBryte(TM) is a novel therapy based on photodynamic therapy, which combines light and a photosensitizer to target and destroy cancer cells.

 The development of treatments for rare diseases remains one of the most pressing challenges in modern medicine. Despite significant advancements in healthcare, many rare diseases still have no approved treatments, and patients often face grim prospects. The market for treatments in this space is substantial, as rare diseases collectively affect millions of people worldwide. Among those working tirelessly to fill these gaps is Soligenix (NASDAQ: SNGX), a biopharmaceutical company that is leading the way with innovative therapies for rare and difficult-to-treat diseases, particularly early-stage cutaneous T-cell lymphoma, a rare form of cancer that affects the skin.

 The global market for rare disease treatments is growing at an impressive rate. According to a report by Grand View Research, the global rare disease treatment market was estimated at $195.2 billion in…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/soligenix-inc-nasdaq-sngx-hybrytetm-paves-way-for-breakthrough-treatment-for-rare-skin-cancer/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/soligenix-s-hybryte-tm-shows-promise-in-rare-skin-cancer-treatment-study/57403b92d84a016d1bfdd4eafb08e257) 

 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1kcfj2q/soligenixs_hybrytetm_shows_promise_in_rare_skin/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/255/1/envyxusZ.webp)